Tratamiento del cáncer de próstata y cáncer renal con fármacos orales (abiraterona y antiangiogénicos): posicionamiento de la Asociación Española de Urología

Villavicencio, H.; Hernández, Carlos; Gómez, Ana M.; Cózar, J.M.; Rodrı́guez-Antolı́n, A.; Prieto, L.; Cabo, M. de; Malet, Juan; Extramiana, J; Mata, João F.; Arrabal, M.; Server, G; Solsona, E.; Valle, Juan W; Miguélez, E.; Gutierrez, Elva Irene Cortes; Elizalde, Arlette; Mateos, J A de Torres; Artiles, J; Jiménez-Cidre, Miguel Ángel; Nalda, L.M.; Cruz, N.G.; Ozonas, M.; Caffaratti, Jorge; Esteban, Mario; Unda, Miguel; Reina, C.; Álvarez-Ossorio, J.L.; Lledó, E.; Angulo, Javier C.

doi:10.1016/j.acuro.2013.04.001

Cited by 3 publications

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The study also showed that second-line hormone decisions were mainly managed by urologists and were infrequently shared with medical and radiation oncologists. This observation could be explained by the sole inclusion of urologists in the study; however, it is to be expected given that hormonal therapies are typically managed by urologists in clinical practice [ 18 ]. The results of a recent analysis of common treatment practices in PCa across Europe showed that Spanish urologists are less involved in managing second-line hormonal therapy (39%) compared with their German (53%) or UK colleagues (80%) [ 5 ].…”

Section: Discussionmentioning

confidence: 99%

Current Patterns of Management of Advanced Prostate Cancer in Routine Clinical Practice in Spain

2015

View full text Add to dashboard Cite

Objective. To describe urologists' practice patterns when managing patients with advanced prostate cancer (PCa) in Spain. Methods. This was an observational study conducted by 120 urologists using retrospective data of advanced PCa patients attending hospitals and outpatient centers. Results. Urologists evaluated a total of 375 patients (mean age: 75 years; ECOG 0-1: 77%; mean serum PSA levels at study entry: 50.5 ng/Ml). Approximately 50% of patients had bone metastases, and 60.6% experienced pain as the main symptom of progressive disease. Primary androgen deprivation therapy (ADT) use was 99.7%, with continuous ADT as the dominant strategy (91.9%). After failure of initial ADT, antiandrogen withdrawal was the next method most commonly used in 57% of patients. Choice of secondary hormonal treatment was made mostly by urologists (96%), who continued to monitor patients. Patient follow-up after chemotherapy and supportive care were mainly done in urology units, although responsibility was shared with medical oncologists and radiologists. Conclusion. The urologists' attitudes towards management of PCa in the routine practice in Spain show the urologist as an integral component even when patients progress to advanced stages of the disease.

show abstract

Section: Discussionmentioning

confidence: 99%